The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...

Cancer immunotherapy biotech I-Mab, has paused the development of uliledlimab ... The trial is also investigating the therapy in combination with Opdivo (nivolumab) and chemotherapy as part ...

Phase 2 data have shown promising efficacy with nivolumab combined with ipilimumab in this patient population, and data already published from the ongoing, phase 3 CheckMate 8HW trial show ...

I-Mab has completed enrollment ahead of schedule ... with givastomig in combination with standard chemotherapy and nivolumab. Overall, the clinical program aims to establish the safety and ...